Association of serum soluble endoglin with preeclampsia

Asma Mehmood; Najma Fida; Afshan Gul; Sahar Farhat; Laila Khalid; Somaya Noor

doi:10.53730/ijhs.v6nS9.12583

Authors

Asma Mehmood Senior Lecturer-Dept. of Biochemistry, Kabir Medical College, Gandhara University Peshawar
Najma Fida Assistant Professor-Dept. of Physiology, Kabir Medical College, Gandhara University Peshawar
Afshan Gul
afshangul889@gmail.com
Assistant Professor-Dept. of Physiology, Kabir Medical College, Gandhara University Peshawar
Sahar Farhat Assistant Professor-Dept. of Physiology, Ayub Medical College, Abbottabad
Laila Khalid Lecturer-Dept. of Physiology, Kabir Medical College, Gandhara University Peshawar
Somaya Noor Lecturer-Dept. of Physiology, Kabir Medical College, Gandhara University Peshawar

Keywords:

Serum soluble endoglin levels, pregnancy, preeclampsia, Blood pressure

Abstract

Objectives: To determine and compare the serum soluble Endoglin (sEng) levels among pregnant women with preeclampsia (PE) and women having normal pregnancy. Methodology: This cross-sectional study was carried at IBMS KMU and the data collection was carried out in the department of Gynecology & obstetrics, Lady Reading hospital, Peshawar, from June 2019 to July 2020. A total of 138 pregnant women at the gestational age of 26-30 weeks were included. The study sample was divided into two groups. Group A: Pre-Eclamptic (n=92). Group B: Normotensive Control Group; women with normal pregnancy (n=46). Results: Mean age in PE group was considerably lower as compared to control group (p<0.001). Similarly, mean age at the time of marriage was significantly lower in the PE group compared to control group (19.40±1.92 vs 21.17±2.19 years, p<0.001). Both mean systolic and diastolic blood pressure in PE and control group was noted to be significantly differed (169.78 ± 16.64/ 114.62 ± 9.34 vs 119.57 ± 1.07/ 78.48 ± 5.56 mm Hg, p<0.05). PE group had statistically significantly higher sEng levels compared to control group (13.42 ± 2.94vs3.47 ± 2.80 ng /ml, p <0.001).

Downloads

Download data is not yet available.

References

Abd El-Dayem TM, Elagwany AS, Khamis MY, Kamha ES, Hassan AMM. Correlation of serum soluble endoglin to the severity of pre-eclampsia and its effect on the pregnancy outcome. Int J Reprod Contracept Obstet Gynecol. 2016;5(5):1594-1600. DOI: 10.18203/2320-1770.ijrcog20161332.

Ali Z, Ali Z, Khaliq S, Zaki S, Ahmad HU, Lone KP. Differential Expression of Placental Growth Factor, Transforming Growth Factor-β and Soluble Endoglin in Peripheral Mononuclear Cells in Preeclampsia. J Coll Physicians Surg Pak. 2019;29(3):235-239. DOI:10.29271/jcpsp.2019.03.235.

Bianco A, Stone J, Lynch L, Lapinski R, Berkowitz G, Berkowitz RL. Pregnancy outcome at age 40 and older. Obstet Gynecol. 1996;87(6):917-922. DOI: 10.1016/0029-7844(96)00045-2.

Hagmann H, Thadhani R, Benzing T, Karumanchi SA, Stepan H. The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin Chem. 2012;58(5):837-845. DOI:10.1373/clinchem.2011.169094.

Jardim LL, Rios DR, Perucci LO, de Sousa LP, Gomes KB, Dusse LM. Is the imbalance between pro-angiogenic and anti-angiogenic factors associated with preeclampsia? Clin Chim Acta. 2015;447:34-38. DOI: 10.1016/j.cca.2015.05.004.

Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, Bossuyt PM, van der Post JA, von Dadelszen P, et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG: Int J Obstet Gynaecol. 2012;119(7):778-787. DOI: 10.1111/j.1471-0528.2012.03311.x.

Leaños-Miranda A, Navarro-Romero CS, Sillas-Pardo LJ, Ramírez-Valenzuela KL, Isordia-Salas I, Jiménez-Trejo LM. Soluble Endoglin As a Marker for Preeclampsia, Its Severity, and the Occurrence of Adverse Outcomes. Hypertension. 2019;74(4):991-997. DOI: 10.1161/hypertensionaha.119.13348.

Margioula-Siarkou G, Margioula-Siarkou C, Petousis S, Margaritis K, Alexandratou M, Dinas K, et al. Soluble endoglin concentration in maternal blood as a diagnostic biomarker of preeclampsia: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021;258:366-381. DOI: 10.1016/j.ejogrb.2021.01.039.

Mohanty S, Nayak N, Nanda NN, Rao P. Serum lipids and malondialdehyde levels in primiparous patients with pregnancy induced hypertension. Indian J Clin Biochem. 2006;21(1):189-192. DOI: 10.1007/bf02913094.

Muhammed LT, Ali EA, Hameed BH. Role Of Soluble Endoglin In The Diagnosis Of Preeclampsia Severity In Iraqi Women. Sys Rev Pharm. 2021;12(1):301-305. DOI:10.31838/srp.2021.1.48.

Nikuei P, Rajaei M, Malekzadeh K, Nejatizadeh A, Mohseni F, AtashAbParvar A. Accuracy of Soluble Endoglin for Diagnosis of Preeclampsia and its Severity. Iran Biomed J. 2017;21(5):312-330. DOI:10.18869/acadpub.ibj.21.5.312.

Ollauri-Ibáñez C, López-Novoa JM, Pericacho M. Endoglin-based biological therapy in the treatment of angiogenesis-dependent pathologies. Expert Opin Biol Ther. 2017;17(9):1053-1063. DOI: 10.1080/14712598.2017.1346607.

Oujo B, Perez-Barriocanal F, Bernabeu C, Lopez-Novoa JM. Membrane and soluble forms of endoglin in preeclampsia. Curr Mol Med. 2013;13(8):1345-1357. DOI: 10.2174/15665240113139990058.

Pasterkamp G, Goumans MJ. The Microvasculature: The Next Battlefield Where Transforming Growth Factor-β and Endoglin Draw Their Double-Edged Swords? Arterioscler Thromb Vasc Biol. 2017;37(1):10-12. DOI: 10.1161/atvbaha.116.308610.

Perucci LO, Gomes KB, Freitas LG, Godoi LC, Alpoim PN, Pinheiro MB, et al. Soluble endoglin, transforming growth factor-Beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia. PLoS One. 2014;9(5):e97632. DOI: 10.1371/journal.pone.0097632.

Sachan R, Patel ML, Dhiman S, Gupta P, Sachan P, Shyam R. Diagnostic and prognostic significance of serum soluble endoglin levels in preeclampsia and eclampsia. Adv Biomed Res. 2016;5:119. DOI: 10.4103/2277-9175.186993.

Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim KH. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol. 2007;197(1):28.e21-26. DOI: 10.1016/j.ajog.2007.04.010.

Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH. Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation. Ultrasound Obstet Gynecol. 2008;32(7):871-876. DOI:10.1002/uog.6126.

Sebire NJ, Jolly M, Harris J, Regan L, Robinson S. Is maternal underweight really a risk factor for adverse pregnancy outcome? A population-based study in London. BJOG: Int J Obstet Gynaecol. 2001;108(1):61-66. DOI: 10.1111/j.1471-0528.2001.00021.x.

Soto E, Romero R, Kusanovic JP, Ogge G, Hussein Y, Yeo L, et al. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med. 2012;25(5):498-507. DOI: 10.3109/14767058.2011.591461.

Staff AC, Braekke K, Johnsen GM, Karumanchi SA, Harsem NK. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. Am J Obstet Gynecol. 2007;197(2):176.e171-176. DOI: 10.1016/j.ajog.2007.03.036.

Wang Y, Chen Q, Zhao M, Walton K, Harrison C, Nie G. Multiple Soluble TGF-β Receptors in Addition to Soluble Endoglin Are Elevated in Preeclamptic Serum and They Synergistically Inhibit TGF-β Signaling. J Clin Endocrinol Metab. 2017;102(8):3065-3074. DOI: 10.1210/jc.2017-01150.